Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Treatment with the long-acting insulin analog degludec during pregnancy in women with type 1 diabetes: An observational study of 22 cases

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Associations between birth weight and glucose intolerance in adulthood among Greenlandic Inuit

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Work matters: Diabetes and worklife in the second diabetes attitudes, wishes and needs (DAWN2) study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Home blood pressure in pregnancy-the upper reference limit

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prevalence of heart failure and other risk factors among first-degree relatives of women with peripartum cardiomyopathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Fatty Liver Among Adolescent Offspring of Women With Type 1 Diabetes (the EPICOM Study)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

AIM: To report glycemic control and pregnancy outcome in pregnant women with type 1 diabetes on insulin degludec.

METHODS: Twenty-two women with type 1 diabetes on degludec from conception to delivery between 2014 and 2018 were compared with 51 pregnant women with type 1 diabetes on glargine.

RESULTS: Baseline characteristics were comparable, however HbA1c was higher at median 9 (range 5-19) weeks in women on degludec compared to women on glargine (6.9% (5.7-8.7); (52 (39-72) mmol/mol) versus 6.4% (5.1-10.1); (46 (32-87) mmol/mol), p = 0.04). HbA1c was similar in late pregnancy (6.3% (5.6-7.1); (45 (38-54) mmol/mol) versus 6.1% (5.2-9.0); (43 (33-75) mmol/mol), p = 0.28). The prevalence of severe hypoglycemia was 3 (14%) versus 6 (12%), p = 1.00 during pregnancy and 0 versus 1, p = 1.00 during hospital admittance after delivery. Most women on degludec used one daily injection in early (20 (91%) versus 25 (49%), p = 0.001) and late pregnancy (21 (96%) versus 19 (37%), p < 0.001). No significant differences in obstetrical and neonatal outcomes were found between the groups. Maternal hospital admittance after delivery was 2 (1-5) versus 3 (2-11) days (p = 0.004).

CONCLUSIONS: Glycemic control in late pregnancy, severe hypoglycemia during and immediately after pregnancy as well as pregnancy outcome were comparable in women on degludec or glargine. Degludec initiated preconceptionally may be continued in pregnancy.

OriginalsprogEngelsk
TidsskriftDiabetes Research and Clinical Practice
Vol/bind152
Sider (fra-til)58-64
Antal sider7
ISSN0168-8227
DOI
StatusE-pub ahead of print - 15 maj 2019

Bibliografisk note

Copyright © 2019 Elsevier B.V. All rights reserved.

ID: 57290897